2Department of Chest Diseases, Dörtyol State Hospital, Hatay-Turkey
3Department of Chest Diseases, Trakya University Faculty of Medicine, Edirne-Turkey OBJECTIVE
The aim of the present study was to investigate nephrotoxicity development ratios and clinical results of nephrotoxicity in patients diagnosed with lung cancer who received cisplatin in chemotherapy protocol.
METHODS
A total of 170 lung cancer patients were enrolled in the present prospective study. Renal functions were
recorded for each patient before and after chemotherapy. Nephrotoxicity was defined as doubling in plasma
creatinine concentration. Modification in treatment due to nephrotoxicity (reduction in cisplatin dosage,
cisplatin interruption, or discontinuation of chemotherapy) was recorded during chemotherapy courses.
RESULTS
Decreasement of creatinine clearance levels was observed following each course of chemotherapy, but
was especially noteworthy following the 1st and 5th courses (p=0.002; p=0.007, respectively). Nephrotoxicity
was observed in 19 of the 170 patients (11%), in 10 of whom (53%) cisplatin dosage was reduced,
and in 8 of whom (42%), cisplatin treatment was interrupted. Chemotherapy was discontinued in 1
patient (5%).
CONCLUSION
Particularly following the fourth course, chemotherapy must be carefully administered due to risk of
nephrotoxicity.